Wednesday, July 29, 2026 - KFF Health News
• Betting platforms Kalshi and Polymarket now allow users to wager on whether the FDA will approve treatments for lung, breast, pancreas, and blood cancers this year. • Kalshi intends to expand its offerings by allowing users to bet on the specific outcomes of clinical drug trials. • Simultaneously, the FDA has reiterated concerns regarding Replimune's lack of adequate data as the biotech company attempts for a third time to gain clearance for a controversial skin cancer drug.
kffhealthnews.org